ClinicalTrials.gg
CompletedNCT03908970Updated Jan 25, 2021Results posted

Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome

A Phase 3 interventional study of 1% OPA-15406 and Placebos in Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
364
Allocation
Randomized
Ages
15 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.

Enrollment
3rd of 16
364 · median 177
Started
2019
with 2 others
Phase 3
10 of 16
2 open now
Registered
7th of 16
by date
Lead sponsor
9 of 16
Otsuka Pharmaceutical Co., Ltd.

Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 3rd largest by enrollment, is one of 3 that started in 2019, is one of 10 in phase 3, and was the 7th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difamilast

difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 15 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing difamilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in adult patients with AD.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
15 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AD based on the Japanese Dermatological Association's criteria
  • History of AD for at least 3 years
  • Atopic dermatitis affecting more than or equal to 5%, to less than or equal to 40% of body surface area (BSA, excluding scalp) at the screening and baseline examinations
  • IGA score of 2 or 3 at the screening and baseline examinations

Exclusion criteria

Exclusion Criteria:

  • Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
364 participants (actual)

Study arms

  • Experimental
    1% OPA-15406

    Twice daily

    Drug: 1% OPA-15406

  • Placebo comparator
    Placebo

    Twice daily

    Drug: Placebos

Interventions

06

What researchers measure

Primary outcomes

  1. Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity

    The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.

    Time frame: At Week 4

Secondary outcomes

  1. Change From Baseline in Eczema Area and Severity Index (EASI) Score

    The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs).

    Time frame: Baseline, Week 4

  2. Change From Baseline in Verbal Rating Scale (VRS) for Pruritus Score

    The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary. 0: None 1. Mild 2. Moderate 3. Severe

    Time frame: Baseline, Week 4

07

Results

Posted Jan 25, 2021

Participant flow

Participant flow — Overall Study
Milestone1% OPA-15406Placebo
Started182182
Completed165135
Not completed1747
Withdrew: Adverse event721
Withdrew: Physician decision14
Withdrew: Withdrawal by subject922

Outcome measures

PrimaryResponder Rate of Investigator's Global Assesment(IGA) of Disease Severity

The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.

Time frame:
At Week 4
Reported as:
Number · percentage of perticipants
Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity
percentage of perticipants1% OPA-15406Placebo
Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity38.46 (31.36 to 45.95)12.64 (8.18 to 18.36)
SecondaryChange From Baseline in Eczema Area and Severity Index (EASI) Score

The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs).

Time frame:
Baseline, Week 4
Reported as:
Mean · score on a scale
Change From Baseline in Eczema Area and Severity Index (EASI) Score
score on a scale1% OPA-15406Placebo
Change From Baseline in Eczema Area and Severity Index (EASI) Score-4.17 ± 0.50-0.08 ± 0.52
SecondaryChange From Baseline in Verbal Rating Scale (VRS) for Pruritus Score

The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary. 0: None 1. Mild 2. Moderate 3. Severe

Time frame:
Baseline, Week 4
Reported as:
Mean · score on a scale
Change From Baseline in Verbal Rating Scale (VRS) for Pruritus Score
score on a scale1% OPA-15406Placebo
Change From Baseline in Verbal Rating Scale (VRS) for Pruritus Score-0.65 ± 0.06-0.04 ± 0.07

Adverse events

Collected over Treatment period (4 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1% OPA-154060/182 (0%)0/182 (0%)7/182 (3.8%)
Placebo0/182 (0%)0/182 (0%)22/182 (12.1%)
Most frequent other events
Most frequent other events
Event1% OPA-15406Placebo
Dermatitis atopicSkin and subcutaneous tissue disorders7/18222/182

Baseline characteristics

Age, Continuous
Age, Continuous(years)1% OPA-15406PlaceboTotal
Mean31.7 ± 10.932.1 ± 10.631.9 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)1% OPA-15406PlaceboTotal
Female8681167
Male96101197
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)1% OPA-15406PlaceboTotal
Asian182182364
Region of Enrollment
Region of Enrollment(Participants)1% OPA-15406PlaceboTotal
Japan182182364
08

Study locations

1 site
  • Kitago Hifuka Clinic
    Sapporo, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Dec 2019, 9 months.

Results were first posted in Jan 2021, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 9 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2019
First posted
Apr 9, 2019
StartActual
Mar 25, 2019
Primary completionActual
Dec 28, 2019
CompletionActual
Dec 28, 2019
Results first posted
Jan 25, 2021
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03908970
Responsible party
Sponsor
First posted
Apr 9, 2019
Start date
Mar 25, 2019
Primary completion
Dec 28, 2019
Completion
Dec 28, 2019
Results posted
Jan 25, 2021
Last update
Jan 25, 2021

Study contacts

Osamu Sato
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difamilast

Start the discussion